FindTrial
Sign In

Clinical Research on the Intervention of Far-Infrared Moxibustion in Patients with Hyperlipidemia

Clinical Efficacy and Underlying Mechanism of Far-Infrared Technology in Hyperlipidemia Patients Based on the Specificity of Meridians and Acupoints

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001463
Enrollment
Unknown
Registered
2025-07-21
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia

Interventions

Sham far-infrared moxibustion group (hereinafter referred to as the "control group"):The control group received sham far-infrared moxibustion intervention
Far-infrared moxibustion group (hereinafter referred to as the "observation group"):The observation group received far-infrared moxibustion intervention.

Sponsors

The Second Affiliated Hospital of Hunan University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Meeting the diagnostic criteria for hyperlipidemia; 2) Aged between 18 and 80 years old; 3) Not concurrently using lipid-regulating medications or having previously used lipid-regulating medications but discontinued them for one month or longer and not participating in any other clinical studies. 4) Enrolled participants have signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Secondary hyperlipidemia caused by other diseases (such as nephrotic syndrome gout hypothyroidism acute or chronic hepatobiliary diseases diabetes etc.); 2) Complicated with severe primary diseases of the liver heart brain etc.; 3) Individuals allergic to far-infrared therapy; 4) Those who have undergone gallbladder surgery or major gastrointestinal surgery within the past 6 months; 5) Individuals with poor compliance.

Design outcomes

Primary

MeasureTime frame
Main indicators of blood lipids: triglycerides total cholesterol high-density lipoprotein cholesterol (HDL-C) low-density lipoprotein cholesterol (LDL-C) leptin apolipoprotein A1 and apolipoprotein B.;—

Secondary

MeasureTime frame
Microbiome testing;TCM (Traditional Chinese Medicine) Symptom Score;Framingham Risk Score;Metabolomics testing;Infrared thermal imaging analysis;(Mini-Mental State ExaminationMMSE);(The FRAIL Scale);(Pittsburgh sleep quality index PSQI);(Hamilton Depression Rating ScaleHAMD)(Hamilton Anxiety ScaleHAMA);Magnetic Resonance Imaging Analysis;—

Countries

China

Contacts

Public ContactMi Liu

Hunan University of Chinese Medicine

newmean@hnucm.edu.cn15116387811

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026